Affordable Access

deepdyve-link
Publisher Website

Approaches for generation of anti-leukemia specific T cells.

Authors
  • Jin, Zhenyi1, 2
  • Xu, Ling1, 3
  • Li, Yangqiu1, 3
  • 1 Key Laboratory for Regenerative Medicine of Ministry of Education; Institute of Hematology, School of Medicine; Jinan University, Guangzhou, 510632, China. , (China)
  • 2 Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou, 510632, China. , (China)
  • 3 Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, China. , (China)
Type
Published Article
Journal
Cell regeneration (London, England)
Publication Date
Dec 01, 2018
Volume
7
Issue
2
Pages
40–44
Identifiers
DOI: 10.1016/j.cr.2018.09.002
PMID: 30671229
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

As three decades ago, it was reported that adoptive T cell immunotherapy by infusion of autologous tumor infiltrating lymphocytes (TILs) mediated objective cancer regression in patients with metastatic melanoma. A new era of T cell immunotherapy arose since the improvement and clinical use of anti-CD19 chimeric antigen receptor T cells (CAR-T) for the treatment of refractory and relapsed B lymphocyte leukemia. However, several challenges and difficulties remain on the way to reach generic and effective T cell immunotherapy, including lacking a generic method for generating anti-leukemia-specific T cells from every patient. Here, we summarize the current methods of generating anti-leukemia-specific T cells, and the promising approaches in the future.

Report this publication

Statistics

Seen <100 times